Fisetin senolytic associated with alleviating COVID-19 dysfunction in older adults in a Phase 2 RCT.
This was a Phase 2 placebo-controlled randomized trial testing fisetin, a senolytic drug, in older adults with COVID-19 in nursing homes. The study aimed to determine whether fisetin could prevent disease progression and reduce inflammatory complications, though the abstract does not report the results, sample size achieved, or magnitude of any effects observed.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 26, 2025 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Older adults in nursing homes with COVID-19
- Primary outcome
- Prevention of disease progression and alleviation of complications due to excessive inflammatory response in COVID-19
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- Aug 26, 2025
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.